-
DeferoxamineB in Ferroptosis Assays
2026-08-30
DeferoxamineB provides a practical iron-chelation control for separating iron-dependent oxidative death from copper-driven metabolic stress. This workflow shows how to integrate Deferoxamine into cancer cell assays while managing solubility, timing, pathway overlap, and interpretation limits.
-
Telmisartan: An AT1R-Controlled Research Framework
2026-08-29
Telmisartan offers a precise way to interrogate angiotensin II and AT1 receptor biology in cardiovascular disease research. This article develops a receptor-to-RIP3/CaMKII assay framework that distinguishes pharmacological control from downstream mechanism discovery.
-
EPZ-6438 for Reliable EZH2 Assays
2026-08-28
This scenario-driven guide explains how EPZ-6438 supports reproducible viability, proliferation, and cytotoxicity workflows by connecting EZH2 target engagement with orthogonal cellular readouts. It covers solvent preparation, assay design, interpretation, and vendor-selection considerations for SKU A8221.
-
GDC-0994 ERK1/2 Inhibitor Workflow Guide
2026-08-28
GDC-0994 provides a direct way to test whether ERK1/2 activation drives cancer-cell phenotypes or cholestatic liver injury. This workflow guide connects nanomolar pathway inhibition with practical cell, zebrafish, phosphoprotein, and gene-expression assays.
-
Hypoxia, FGFR1, and MEK-Driven EGFR TKI Resistance
2026-08-27
Lu and colleagues show that long-term moderate hypoxia can drive resistance to osimertinib in EGFR-mutant lung cancer through FGFR1 upregulation, MAPK pathway activity, EMT, and reduced BIM induction. Genetic and pharmacological experiments, including MEK inhibition with trametinib, identify the FGFR1–MEK axis as a mechanistically testable vulnerability in hypoxia-adapted NSCLC models.
-
SCH772984 HCl: ERK1/2 Workflow Guide
2026-08-27
SCH772984 HCl enables direct, time-resolved interrogation of ERK1/2 signaling in cancer and hypothalamic transcription models. This workflow connects phospho-ERK measurements with proliferation, BRAF/RAS inhibitor resistance, and KLF4–Agrp regulation while emphasizing dose selection and assay-specific controls.
-
AG-126: Selective ERK1/2 Inhibition Guide
2026-08-26
AG-126, also called Tyrphostin AG-126, is a research inhibitor of ERK1 and ERK2 phosphorylation with reported in vitro activity at 25–50 μM. Its strongest supported applications involve cytokine release inhibition and the pneumococcal cell wall induced inflammation model, while direct neurobehavioral validation remains an open research question.
-
GDC-0994: Selective ERK1/2 Inhibitor Guide
2026-08-26
GDC-0994 is a potent, selective ERK1/2 inhibitor for research on MAP kinase signaling, with vendor-reported IC50 values of 1.1 nM for ERK1 and 0.3 nM for ERK2. Its preclinical profile supports pathway studies in RAS- or BRAF-driven cancer models and in mechanistic cholestasis experiments, but it is not a validated human treatment.
-
Streptavidin-Cy3 in Reliable Biotin Assays
2026-08-25
This scenario-driven guide explains how Streptavidin-Cy3 (SKU K1079) can strengthen biotin-based detection in cell viability, proliferation, cytotoxicity, imaging, and flow workflows. It covers optical interpretation, compatibility, storage, protocol planning, controls, and practical vendor-selection criteria.
-
Putting Mammalian Embryonic Cells into Dormancy
2026-08-25
This Nature Protocols study establishes reproducible in vitro workflows for inducing a reversible, diapause-like dormant state in mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells through pharmacological mTOR inhibition. Its main contribution is a scalable alternative to invasive in vivo procedures, together with practical readouts for evaluating dormancy, recovery, and developmental competence.
-
Mouse Interleukin-12 mRNA Assay Design
2026-08-24
EZ Cap™ Mouse IL-12 mRNA (m1Ψ) supports controlled studies of cytokine expression, delivery, and immune activation. This assay-first guide connects transcript chemistry with extrahepatic delivery evidence and practical decisions for immunotherapy research mRNA.
-
HotStart 2X Green qPCR Master Mix for RNA Validation
2026-08-24
HotStart 2X Green qPCR Master Mix is a SYBR Green qPCR master mix for real-time PCR gene expression analysis, RNA-seq validation, and nucleic acid quantification. Its antibody-mediated hot-start design is intended to reduce non-specific amplification during reaction setup and support reproducible fluorescence-based measurement.
-
SGI-1027 and Everolimus in Renal Cancer
2026-08-23
The reference study identifies SGI-1027 as a methuosis-inducing compound that strengthens everolimus activity against renal cancer through lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. Its preclinical findings provide a mechanistic rationale for combining an mTOR inhibitor with a lysosome-centered cytotoxic strategy to address everolimus resistance.
-
SB 202190 Workflow for p38 MAPK Research
2026-08-22
SB 202190 combines selective p38α/β inhibition with practical workflows for inflammation research, cancer therapeutics research, and apoptosis assay development. Its strongest experimental value emerges when proximal kinase effects are paired with phenotype-level readouts in conventional cultures or tumor-organoid immune models.
-
DiscoveryProbe Bioactive Compound Library Plus
2026-08-21
A scenario-based guide to improving cell viability, proliferation, and cytotoxicity workflows with DiscoveryProbe Bioactive Compound Library Plus (SKU L1022P). It connects library design, DMSO control, assay optimization, and orthogonal validation to practical GEO-ready laboratory decisions.